Definium Therapeutics (NASDAQ:DFTX) Sees Large Volume Increase – Here’s Why

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) saw unusually-strong trading volume on Monday . Approximately 1,217,849 shares traded hands during trading, a decline of 34% from the previous session’s volume of 1,855,422 shares.The stock last traded at $22.89 and had previously closed at $23.55.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on DFTX shares. Piper Sandler reissued an “overweight” rating and set a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Leerink Partners lifted their target price on shares of Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Canaccord Genuity Group set a $38.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 16th. Stifel Nicolaus set a $30.00 target price on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 16th. Finally, Oppenheimer restated an “outperform” rating and issued a $40.00 price target on shares of Definium Therapeutics in a report on Thursday, April 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $37.92.

Definium Therapeutics Trading Down 4.4%

The business has a fifty day moving average of $21.84 and a 200-day moving average of $17.54. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The company has a market capitalization of $2.24 billion, a P/E ratio of -9.04 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Analysts anticipate that Definium Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Palumbo Wealth Management LLC lifted its stake in shares of Definium Therapeutics by 18.4% in the fourth quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock valued at $522,000 after buying an additional 6,073 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Definium Therapeutics in the fourth quarter valued at $117,000. Bay Rivers Group lifted its stake in shares of Definium Therapeutics by 14.3% in the fourth quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after buying an additional 2,000 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Definium Therapeutics in the third quarter valued at $107,000. Finally, Caxton Associates LLP purchased a new stake in shares of Definium Therapeutics in the third quarter valued at about $126,000. 27.91% of the stock is owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.